Martin W. Schoen, MD, MPH

Articles by Martin W. Schoen, MD, MPH

Martin Schoen, MD, and Andrew W. Hahn, MD

Treatment Intensification in Vulnerable Populations: ARPI Use in Elderly, Frail, and High-Comorbidity Patients With mCSPC: With Martin Schoen, MD, and Andrew W. Hahn, MD

ByMartin W. Schoen, MD, MPH,Andrew W. Hahn, MD

June 30th 2026

Martin Schoen, MD, and Andrew W. Hahn, MD, discuss ARPI use in elderly, frail, and high-comorbidity patients with mCSPC

Martin W. Schoen, MD, MPH

Dr Schoen on a Real-World Study of Enzalutamide vs Apalutamide in mCSPC

ByMartin W. Schoen, MD, MPH

May 18th 2026

Martin W. Schoen, MD, MPH, discusses data from a real-world study of enzalutamide vs apalutamide in mCSPC.

Latest Updated Articles

Treatment Intensification in Vulnerable Populations: ARPI Use in Elderly, Frail, and High-Comorbidity Patients With mCSPC: With Martin Schoen, MD, and Andrew W. Hahn, MD
June 30th 2026

Trending on OncLive

FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer

FDA Grants Breakthrough Device Designation to Natera’s Multi-Cancer Early Detection Assay

VIR-5500 Receives FDA Fast Track Designation in mCRPC

MAVERICK, B7-H3–Directed ADCs, and ADAURA Data Headline Key Lung Cancer Findings From WCLC 2026

Iberdomide Plus Daratumumab/Dexamethasone Yields Significant PFS Benefit in R/R Myeloma